Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma

Journal of Clinical Pathology

Volumn 64, Issue 11, 2011, Pages 953-959

  Huang, Ying ^a   Chen, Xueqin ^a   Chen, Ni ^a   Nie, Ling ^a   Xu, Miao ^a   Zhou, Qiao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MESSENGER RNA PRECURSOR; SURVIVIN;

ALTERNATIVE RNA SPLICING; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; ALTERNATIVE SPLICING; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PRECURSORS;

EID: 80054884813     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200066     Document Type: Article

References (53)

1. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
2. Louis DN, Ohgaki H, Wiestler OD, et al. World Health Organization of Tumours of the Central Nervous System. Lyon: IARC Press, 2007.
3. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
4. Chen J, Wu W, Tahir SK, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000;2:235-41.
5. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-6.
6. Skoufias DA, Mollinari C, Lacroix FB, et al. Human survivin is a kinetochoreassociated passenger protein. J Cell Biol 2000;151:1575-82.
7. Altieri DC. New wirings in the survivin networks. Oncogene 2008;27:6276-84.
8. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-8.
9. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, et al. Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 2003;127:826-33.
10. Liu X, Chen N, Wang X, et al. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. J Neuropathol Exp Neurol 2006;65:905-13.
11. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
12. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004;314:902-7.
13. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
14. Vietri M, Molinari AM, Schiavone E, et al. Identification of a novel survivin splicing variant 3alpha in acute myeloid leukemia 2006. http://www.ncbi.nlm.nih.gov/ nuccore/83744165 (accessed 4 Jun 2011).
15. Noton EA, Colnaghi R, Tate S, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006;281:1286-95.
16. Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev 2009;32:308-13.
17. Cheng Z, Hu L, Fu W, et al. Expression of survivin and its splice variants in gastric cancer. J Huazhong Univ Sci Technolog Med Sci 2007;27:393-8.
18. Meng H, Lu C, Mabuchi H, et al. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004;216:147-55.
19. Nakano J, Huang C, Liu D, et al. The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer 2008;98:1109-17.
20. Ryan B, O'Donovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005;92:120-4.
21. Suga K, Yamamoto T, Yamada Y, et al. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 2005;13:891-7.
22. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-43.
23. Futakuchi H, Ueda M, Kanda K, et al. Transcriptional expression of survivin and its splice variants in cervical carcinomas. Int J Gynecol Cancer 2007;17:1092-8.
24. Okamura K, Koike H, Sekine Y, et al. Survivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiol 2009;33:137-41.
25. Ling X, Yang J, Tan D, et al. Differential expression of survivin-2B and survivin- DeltaEx3 is inversely associated with disease relapse and patient survival in nonsmall- cell lung cancer (NSCLC). Lung Cancer 2005;49:353-61.
26. Das A, Tan WL, Teo J, et al. Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 2002;128:302-6.
27. Saito T, Arifin MT, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 2007;82:193-8.
28. Sasaki T, Lopes MB, Hankins GR, et al. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 2002;104:105-9.
29. Xie D, Zeng YX, Wang HJ, et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer 2006;94:108-14.
30. Rousseau A, Kujas M, Bergemer-Fouquet AM, et al. Survivin expression in ganglioglioma. J Neurooncol 2006;77:153-9.
31. Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 2003;97:1077-83.
32. Li XN, Shu Q, Su JM, et al. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 2007;33:67-76.
33. Yamada Y, Kuroiwa T, Nakagawa T, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99:738-45.
34. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92:359-65.
35. Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 2009;284:10004-12.
36. Chen X, Gong J, Zeng H, et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010;70:2728-38.
37. Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003;116:1653-8.
38. Spellman R, Rideau A, Matlin A, et al. Regulation of alternative splicing by PTB and associated factors. Biochem Soc Trans 2005;33:457-60.
39. Caldas H, Fangusaro JR, Boue DR, et al. Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood 2007;109:1479-89.
40. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005;24:1994-2007.
41. Hu H, Shikama Y, Matsuoka I, et al. Terminally differentiated neutrophils predominantly express survivin-2 alpha, a dominant-negative isoform of survivin. J Leukoc Biol 2008;83:393-400.
42. Lopes R, Castro I, Pontes P, et al. Expression profile of survivin in acute leukaemias: the importance of differential splicing. Leukemia 2005;19:1284-6.
43. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-16.
44. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004;22:535-46.
45. Troger A, Siepermann M, Mahotka C, et al. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr 2007;219:127-33.
46. Fujino K, Ueda M, Takehara M, et al. Transcriptional expression of survivin and its splice variants in endometriosis. Mol Hum Reprod 2006;12:383-8.
47. Shirai K, Suzuki Y, Oka K, et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 2009;91:353-8.
48. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007;4:174-91.
49. Conway EM, Pollefeyt S, Cornelissen J, et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 2000;95:1435-42.
50. Ling X, Cheng Q, Black JD, et al. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem 2007;282:27204-14.
51. Vegran F, Boidot R, Oudin C, et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007;26:290-7.
52. Span PN, Tjan-Heijnen VC, Heuvel JJ, et al. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem 2006;52:1693-700.
53. Li F. Survivin study: what is the next wave? J Cell Physiol 2003;197:8-29.